



March 31, 2020

BSE Limited

P. J. Towers, 25th Floor,
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza
Bandra Kurla Complex
Bandra (E),
Mumbai - 400 051

Dear Sirs,

Sub.: Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Update on Company's position with respect to COVID-19 pandemic

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on April 1, 2020 at 5.00 p.m. to update the Company's position with respect to COVID-19 pandemic. Details of the Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624



Jubilant Life Sciences Limited
1A, Sector 16A, Noida 201301, India
Tel. : +91 120 4361000
www.jubl.com

Noida, Tuesday, March 31, 2020

Conference call on Wednesday, April 1, 2020 at 05:00 pm IST

The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host a **conference call for analysts and investors on Wednesday, April 1, 2020 at 05:00 pm IST**. The call will commence with a brief by the management team to update on the company's position with respect to COVID-19 pandemic, followed by an interactive Question & Answer session.

Conference Dial-In Numbers	
Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
Local Access Number:	+91-7045671221 <i>Available all over India.</i>
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Replay Facility:	Available from April 01 to 07, 2020 Dial in No.: +91 22 7194 5757 Playback ID: #54365

-ENDS -

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharma business, through Jubilant Pharma Limited, Singapore (JPL), is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics. DDS provides innovation and collaborative research through two world-class research centers in India and Jubilant Therapeutics is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 7,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information please contact:

Vineet Mayer
Jubilant Life Sciences Limited
Ph: +91-120 4361021
E-mail: vineet.mayer@jubl.com

Siddharth Rangnekar / Karl Kolah
CDR India
Ph: +91-22 6645 1209 / 20
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

Disclaimer: *Statements made on the call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*